Barclays Reaffirms Equal Weight Rating for GSK (LON:GSK)

Barclays restated their equal weight rating on shares of GSK (LON:GSK) in a research note issued to investors on Monday morning, MarketBeat reports. They currently have a GBX 1,725 ($21.83) price objective on the stock.

A number of other analysts have also recently commented on GSK. Shore Capital reiterated a buy rating on shares of GSK in a research report on Thursday, March 7th. Berenberg Bank lifted their target price on GSK from GBX 1,650 ($20.88) to GBX 1,820 ($23.04) and gave the stock a buy rating in a research report on Wednesday, February 14th. Finally, Deutsche Bank Aktiengesellschaft reiterated a buy rating and set a GBX 1,950 ($24.68) target price on shares of GSK in a research report on Tuesday, March 12th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of Hold and a consensus target price of GBX 1,630.63 ($20.64).

GSK Stock Up 0.3 %

GSK opened at GBX 1,621 ($20.52) on Monday. The business’s 50-day simple moving average is GBX 1,665.13 and its 200-day simple moving average is GBX 1,541.26. The company has a debt-to-equity ratio of 140.82, a quick ratio of 0.73 and a current ratio of 0.88. GSK has a one year low of GBX 1,302.60 ($16.49) and a one year high of GBX 1,719.80 ($21.77). The stock has a market capitalization of £66.30 billion, a P/E ratio of 1,350.83, a price-to-earnings-growth ratio of 1.15 and a beta of 0.26.

GSK Increases Dividend

The firm also recently disclosed a dividend, which will be paid on Thursday, April 11th. Shareholders of record on Thursday, February 22nd will be issued a GBX 16 ($0.20) dividend. This represents a yield of 1.04%. The ex-dividend date is Thursday, February 22nd. This is a positive change from GSK’s previous dividend of $14.00. GSK’s payout ratio is currently 5,333.33%.

Insider Buying and Selling at GSK

In other GSK news, insider Urs Rohner acquired 434 shares of the stock in a transaction on Wednesday, March 20th. The shares were bought at an average price of GBX 1,662 ($21.04) per share, with a total value of £7,213.08 ($9,129.33). In other news, insider Emma Walmsley sold 139,792 shares of GSK stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.98), for a total transaction of £2,317,751.36 ($2,933,491.15). Also, insider Urs Rohner purchased 434 shares of GSK stock in a transaction dated Wednesday, March 20th. The shares were bought at an average price of GBX 1,662 ($21.04) per share, with a total value of £7,213.08 ($9,129.33). In the last 90 days, insiders have acquired 19,802 shares of company stock valued at $31,381,484. 2.23% of the stock is owned by corporate insiders.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.